Ethnic,clinical and immunological factors in systemic lupus erythematosus and the development of lupus nephritis: results from a multi-ethnic New Zealand cohort

Abstract

The aim of this study was to identify risk factors for lupus nephritis including clinical, laboratory, and ethnic factors in a cohort of lupus patients in New Zealand. A retrospective study of patients from two teaching hospitals in Auckland, New Zealand. Patients were selected if they had attended as either an inpatient, or a rheumatology outpatient between 2000 and 2005. 170 patients had SLE according to ACR classification. Lupus nephritis (LN) was diagnosed according to ACR criteria. Clinical, laboratory, and ethnic data were gathered from the patient notes. Twenty-four patients had LN at diagnosis and 32 patients developed LN after diagnosis. LN was associated with serositis (P = 0.008), cutaneous vasculitis (P = 0.026), anaemia (P = 0.005), CRP elevation >6 months (P < 0.001), hypocomplementaemia >6 months (P < 0.0001). Patients with elevated doublestranded DNA (dsDNA) (>5 × normal) were more likely to develop type IV LN (P = 0.0096). Forty-one percent of patients were Caucasian, 12% Maori, 23% Pacific People, 16% Asian, 6% Indian. Maori patients with SLE (odds ratio (OR) = 8.47, 95% confidence interval (CI) = 2.11—33.96, P = 0.002), and Pacific People (OR = 3.11, 95% CI = 1.29—11.48, P = 0.014) had increased risk for developing LN. Anaemia at presentation (hazard ratio (HR) 3.2, 95% CI = 1.4—7.1, P = 0.004), and low complement >6 months (HR = 3.4, 95% CI = 1.4—8.7, P = 0.008) were independent risk factors for developing LN after SLE diagnosis. In New Zealand, Pacific People and Maori patients with SLE have a higher incidence of LN, and patients with anaemia and hypocomplementaemia are more likely to develop LN after diagnosis. Patients with high dsDNA levels are more likely to develop Type IV lupus nephritis. Lupus (2007) 16, 830—837.

Keywords

anaemia dsDNA lupus nephritis Maori systemic lupus erythematosis

Get full access to this article

View all access options for this article.

References

Kewalramani R. , Singh AK Immunopathogenesis of lupus and lupus nephritis: recent insights. Curr Opin Nephrol Hypertens 2002; 11: 273—277.

Boumpas DT , Austin HA , Fessler BJ , Balow JE , Klippel JH , Lockshin MD Systemic lupus erythematosus: emerging concepts. Part 1: renal, neuropsychiatric, cardiovascular, pulmonary and haematologic disease. Ann Intern Med 1995; 122: 940—950.

Oates JC , Gilkeson GS Mediators of injury in lupus nephritis. Current Opinion Rheumatol 2002; 14: 498—503.

Lee PT , Fang HC , Chen CL , Chiou YH , Chou KJ , Chung HM Poor prognosis of end-stage renal disease in systemic lupus erythematosus: a cohort of Chinese patients. Lupus 2003; 12: 827—832.

Bujan S. , Ordi-Ros J. , Paredes J. et al. Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients . Ann Rheum Dis 2003; 62: 859—865.

Cortes-Hernandez J. , Ordi-Ros J. , Labrador M. et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003; 12: 287—296.

Koffler D. , Agnello V. , Thoburn R. , Kunkel HG SLE, prototype of immune complex nephritis in man. J Exp Med 1971; 134(Suppl): 169s—179s.

Appel GB , Pirani CL , D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 1994; 4: 1499—1515.

Hochberg MC , Petri M. Clinical features of systemic lupus erythematosus. Current Opin Rheum 1993; 5: 575—586.

10.

Lefkowith JB , Gilkeson GS Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum 1996; 39: 894—903.

11.

Lewis EJ , Schwartz MM Pathology of lupus nephritis. Lupus 2005; 14: 31—38.

12.

Waldman M. , Madaio Mpp. Pathogenic autoantibodies in lupus nephritis. Lupus 2005; 14: 19—24.

13.

Zimmerman R. , Radhakrishnan J. , Baleri A. , Appel G. Advances in the treatment of lupus nephritis . Ann Rev Med 2001; 52: 63—78.

14.

Rekvig OP , Kalaaji M. , Nossent H. Anti-DNA antibody subpopulations and lupus nephritis. Autoimmunity Reviews 2004; 3: 1—6.

15.

Wallace DJ Dubois, lupus erythematosus. In W allace, DJ , Hahn, BH eds. The clinical presentation of systemic lupus erythematosus. Williams and Wilkins, 1996; 627.

16.

Alba P. , Bento L. , Cuadrado MJ et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 2003; 62: 556—560.

17.

Arbuckle MR , James JA , Dennis GJ et al. Rapid progression to diagnosis among African-American men with systemic lupus erythematosus. Lupus 2003; 12: 99—106.

18.

Massardo L. , Martinez ME , Jacobelli S. , Villarroel L. , Rosenberg H. , Rivero S. Survival of Chilean patients with systemic lupus erythematosus. Arthritis & Rheum 1994; 24: 1—11.

19.

Al Attia HM , Al Ahmed YH , Chandani AU Serological markers in Arabs with lupus nephritis. Lupus 1998; 7: 198—201.

20.

Mok CC , Tang Ssk. Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus. Am J Med 2004; 117: 791—795.

21.

Mok CC , Lau CS , Chan TM , Wong Rws. Clinical characteristics and outcome of southern Chinese males with systemic lupus erythematosus. Lupus 1999; 8: 188—196.

22.

Hopkinson ND , Jenkinson C. , Muir KR , Doherty M. , Powell RJ Racial group, socioeconomic status, and the development of persistent proteinuria in systemic lupus erythematosus. Ann Rheum Dis 2000; 59: 116—119.

23.

Toloza Sma , Roseman JM , Alarcon GS et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) . Arthritis & Rheum 2004; 50: 3177—3186.

24.

Li Thi Huong D. , Papo T. , Beaufils H. et al. Renal involvement in systemic lupus erythematosus: a study of 180 patients from a single center. Medicine 1999; 78: 148—166.

25.

Marto N. , Bertolaccini ML , Calabuig E. , Hughes Grv , Khamashta MA Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 444—448.

26.

Bastian HM , Roseman JM , McGwin Jr G. et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. (LUMINA Study Group). Lupus 2002; 11: 152—160.

27.

Sasaki T. , Muryoi T. , Hatakeyama A. et al. Circulating anti-DNA immune complexes in active lupus nephritis . Am J Med 1991; 91: 355—362.

28.

Ravirajan CT , Rowse L. , MacGowan JR , Isenberg DA An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus. Rheumatology 2001; 40: 1405—1412.

29.

Forger F. , Matthias T. , Oppermann M. , Becker H. , Helmke K. Clinical significance of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus 2004; 13: 36—44.

30.

Naiker IP , Rughubar KN , Duursma J. , Pudifin DJ , Seedat YK Anticardiolipin antibodies in South African patients with lupus nephritis: a clinical and renal pathological study. Am J Nephrol 2000; 20: 351—357.

31.

Loizou S. , Samarkos M. , Norsworthy PJ , Cazabon JK , Walport MJ , Davies KA Significance of anticardiolipin and anti-B2-glycoprotein I antibodies in lupus nephritis. Rheumatology 2000; 39: 962—968.

32.

Font J. , Cervera R. , Ramos-Casals M. et al. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Seminars in Arthritis and Rheumatism 2004; 33: 217—230.

33.

Daugas E. , Nochy D. , Huong Dlt et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus . J Am Soc Nephrol 2002; 13: 42—52.

34.

Migliorini P. , Baldini C. , Rocchi V. , Bombadieri S. Anti-Sm and Anti-RNP antibodies. Autoimmunity 2005; 38: 47—54.

35.

Fremeaux-Bacchi V. , Noel LH , Schifferli JA No lupus nephritis in the absence of antiC1q autoantibodies? Nephrol Dial Transplant 2002 ; 17: 2041—2043.

36.

Porcel JM , Ordi J. , Castro-Salomo A. et al. The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin Immunol and Immunopath 1995; 74: 283—288.

37.

Williams W. , Shah D. , Sargeant LA The clinical and epidemiologic features in 140 patients with lupus nephritis in a predominantly black population from one center in Kingston, Jamaica. Am J Med Sci 2004; 327: 324—329.

38.

Ward MM , Studenski S. Clinical prognostic factors in lupus nephritis: the importance of hypertension and smoking. Arch Intern Med 1992; 152: 2082—2088.

39.

Barr RG , Seliger S. , Appel GB et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrology Dialysis Transplantation 2003; 18: 2039—2046.

40.

Wada Y. , Satoshi I. , Ueno M. et al. Renal outcome and predictors of clinical renal involvement in patients with silent lupus nephritis. Nephron Clin Pract 2004; 98: c105—c111.

41.

Tan EM , Cohen AS , Fries JF The 1982 revised criteria for the classification of the systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271—1277.

42.

Hochburg MC Updating the American College of Rheumatology revisited criteria for the classification of SLE. Arthritis Rheum 1997; 40: 1725.

43.

Balow JE Clinical presentation and monitoring of lupus nephritis. Lupus 2005; 14: 25—30.

44.

Vila LM , Alarcon GS , Mc Gwin Jr G. et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. J Rheum 2005; 32: 2150—2155.

45.

Witte T. , Hartung K. , Sachse S. et al. IgM anti-dsDNA antibodies in systemic lupus erythematosus: negative association with nephritis. Rheumatol Int 1998; 18: 85—91.

46.

Hart HH , Grigor RR , Caughey DE Ethnic difference in the prevalence of systemic lupus erythematosus. Ann Rheum Dis 1983; 42: 529—532.

47.

Petri M. , Perez-Gutthanns S. , Longenecker JC , Hochberg M. Morbidity of systemic lupus erythematosus: Tole of race and socio-economic status. Am J Med 1991; 91: 345—353.

48.

McAlindon T. , Gianotta L. , Taub N. , D'Cruz D, Hughes G. Environmental factors predicting nephritis in systemic lupus erythematosus. Ann Rheum Dis 1993; 52: 720—724.

49.

Studenski S. , Allen N. , Caldwell D. , Rice J. , Polisson R. Survival in systemic lupus erythematosus. A multivariate analysis of demographic factors. Arthritis Rheum 1987; 30: 1326—1332.

50.

Dooely MA , Hogan S. , Jennette C. , Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997; 51: 1188—1195.

51.

Ward M. , Studenski S. Clinical manifestations of systemic lupus erythematosus. Identification of racial and socio-economic factors. Arch Intern Med 1990; 150: 849—853.

52.

Mok CC Prognostic factors in lupus nephritis. Lupus 2005; 14: 39—44.

53.

Thompson CF , Simmons D. , Collins JF et al. Predisposition to nephropathy in Polynesians is associated with family history of renal disease, not diabetes mellitus . Diabet Med 2001; 18: 40—46.

54.

Adler S.

Renal disease: environment, race, or genes?

Ethn Dis 2006; 16(Suppl 2): 35—39.

55.

Kyle CV , Abbott W. , Young RP et al. Angiotensin-1-converting enzyme and angiotensinogen gene polymorphisms in Maori and Pacific Island people in New Zealand. Intern Med J 2001; 31: 116—118.

56.

Menon V. , Greene T. , Wang X. et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68: 766—772.

57.

Muntner P. , Hamm LL , Kusek JW , Chen J. , Whelton PK , He J. The prevalence of non-traditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004; 140: 9—17.

58.

Barnes EV , Narain S. , Naranjo A. et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005; 14: 576—582.

59.

Williams RC Jr , Harmon ME , Burlingame R. , Du Clos T W. Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheumatol 2005; 32: 454—461.

60.

Wais T. , Fierz W. , Stoll T. , Villiger PM Subclinical disease activity in systemic lupus erythematosus: immuno-inflammatory markers do not normalize in clinical remission. J Rheumatol 2003; 30: 2133—2139.